AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06649448
Drug: Efbemalenograstim alfa Injection
RxNorm normalized name: efbemalenograstim alfa
DrugBank: Efbemalenograstim alfa (DB18704)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This product should be administered subcutaneously 48 hours after the completion of anti-tumor drug administration in each chemotherapy cycle. The recommended dose for adults is 20mg administered subcutaneously once per chemotherapy cycle. Please do not administer this product within 14 days before and 24 hours after the administration of cytotoxic chemotherapy drugs.
Trial: NCT06649448
Drug: carboplatin/cisplatin-etoposide
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one of the following chemotherapy regimens can be selected: EC, Q3W: Carboplatin AUC = 5\~6 on Day 1; Etoposide 80\~100 mg/m² on Days 1-3. EP, Q3W: Cisplatin 75\~80 mg/m² on Day 1; Etoposide 80\~100 mg/m² on Days 1-3.
Trial: NCT06649448
Drug: Carboplatin plus Paclitaxel
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For non-small cell lung cancer (squamous cell carcinoma), one of the following chemotherapy regimens can be selected:~Carboplatin AUC = 5\~6 on Day 1 + Taxane: Paclitaxel 175-200 mg/m² on Day 1; or Albumin-bound Paclitaxel 200-260 mg/m² on Day 1, administered every 3 weeks (Q3W); Cisplatin/Carboplatin 75 mg/m²/AUC = 5\~6 on Day 1 + Gemcitabine 1000 mg/m² on Days 1 and 8, administered every 3 weeks (Q3W).
Trial: NCT06649448
Drug: Cisplatin/pemetrexed or Carboplatin/pemetrexed
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For non-small cell lung cancer (non-squamous cell carcinoma), one of the following chemotherapy regimens can be selected:~Cisplatin 75 mg/m² on Day 1 + Pemetrexed 500 mg/m² on Day 1, administered every 3 weeks (Q3W).~Carboplatin AUC = 5\~6 on Day 1 + Pemetrexed 500 mg/m² on Day 1, administered every 3 weeks (Q3W).
Trial: NCT04313959
Drug: Ropivacaine 0.2% Injectable Solution
RxNorm normalized name: ROPivacaine 0.2% injectable solution
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-shot ultrasound-guided erector spine plane block of 0.2% ropivacaine
Trial: NCT04313959
Drug: Ropivacaine 0.2% + Dexamethasone
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Addiction of 5 mg/ml dexamethasone in 0.2% ropivacaine solution
Trial: NCT04493151
Drug: Imipenem, Cilastatin and Relebactam
RxNorm normalized name: imipenem, cilastatin and relebactam
DrugBank: Cilastatin (DB01597)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After receipt of imipenem-cilastatin-relebactam, ten blood samples will be collected to determine the pharmacokinetics of imipenem and relebactam.
Trial: NCT05603156
Drug: the usage of Olverembatinib combined with Inotuzumab Ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: patients in this arm will accept a 28 days treatment regimen: Olverembatinib 40mg QOD (d1 to d28 )and Inotuzumab Ozogamicin 1.2mg/m2 (divided into 2 days, d1 and d8, 0.6mg/m2, respectively).
Trial: NCT04806646
Drug: Sonidegib
RxNorm normalized name: Sonidegib
DrugBank: Sonidegib (DB09143)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: TS1: assumption 14 days on and 14 days off. TS2: assumption 7 days on and 21 days off.
Trial: NCT05073172
Drug: Calendula Ointment
RxNorm normalized name: CALENDULA
DrugBank: Calendula officinalis whole (DB14315)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied topically
Trial: NCT05967182
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by IV (vein)
Trial: NCT05967182
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by IV (vein)
Trial: NCT05967182
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by IV (vein)
Trial: NCT05073172
Drug: Silicone-based Film Forming Topical Gel
RxNorm normalized name: silicones Topical Cream
DrugBank: Silicon (DB12982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied topically
Trial: NCT05073172
Drug: Silver Sulfadiazine
RxNorm normalized name: Silver Sulfadiazine
DrugBank: Silver sulfadiazine (DB05245)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied topically
Trial: NCT06509971
Drug: QL1706
RxNorm normalized name: QL1706
DrugBank: QL1706 (DB17562)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Order of Drug Administration was: QL1706→ bevacizumab → albumin-binding paclitaxel, and each drug was administered at least 30 minutes apart.~QL1706: 5 mg/kg Q3W. The infusion time was 30 minutes + 5 minutes. No dose adjustment was allowed for QL1706 during treatment, but delayed administration was allowed, with a delay of no more than 4 weeks from the previous dose.~Albumin-binding paclitaxel: 260 mg/m 2 Q3W, IV, for 30 min + 5 min. During treatment, albumin-binding paclitaxel allows for dose adjustments.~Bevacizumab: 15 mg/kg Q3 W, iv. The first infusion should last 90 minutes. If the first infusion was well tolerated, the second infusion could be shortened to 60 minutes. If the patient is also well-tolerated for a 60-minute infusion, then all subsequent infusions can be completed in 30 minutes, no dose adjustment is allowed for bevacizumab.
Trial: NCT06319846
Drug: Tirofiban
RxNorm normalized name: Tirofiban
DrugBank: Tirofiban (DB00775)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initial infusion of tirofiban 0.4μg/kg body weight/minute for 30 minutes (a maximum dose of 1mg) within 24 hours of symptom onset, followed by a continuous infusion of tirofiban 0.1μg/kg body weight/minute for 48 hours.
Trial: NCT05215912
Drug: TNB-738
RxNorm normalized name: TNB-486
DrugBank: TNB-486 (DB19420)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNB-738 is an investigation drug. Other: Matching placebo
Trial: NCT06631326
Drug: Lenvatinib + PD-1 monoclonal antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PD-1 inhibitors including Camrelizumab, Sintilimab, Tislelizumab
Trial: NCT05663944
Drug: Sirolimus 0.5Mg Tab
RxNorm normalized name: SIROLIMUS 0.5MG TAB
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Once randomised, participants will receive either sirolimus or placebo daily for 6 months. Participants will start on a dose of 1mg daily (2 x 0.5mg tablets) and will have weekly routine bloods including full blood count, renal function and electrolytes and liver function test along with sirolimus trough levels measured to determine the next dose. The aim will be to achieve a steady state blood trough level of 3-7 ng/ml, which is usually achieved in 3-5 weeks. Placebo will also be started at 2 capsules daily. All participants will undergo weekly blood tests for the first 3-5 weeks and placebo doses will be adjusted randomly to maintain blinding.~All participants will be reviewed by a research clinician at 2, 4 and 6 months.
Trial: NCT06495541
Drug: Pyrotinib
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration method: Pyrrolitinib standard dose: 400 mg once a day, oral administration within 30 minutes after breakfast, continuous administration for 21 days per cycle. The dosage can be determined by the doctor according to the actual situation Make adjustments. Other medications: The doctor selects the medication plan based on the actual situation.
Trial: NCT06241183
Drug: Intravenous Famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in this group will receive 20mg IV Famotidine.
Trial: NCT04500665
Drug: Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colchicine
Trial: NCT00002409
Drug: Lamivudine/Zidovudine
RxNorm normalized name: LAMIVUDINE/ZIDOVUDINE
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002409
Drug: Abacavir sulfate
RxNorm normalized name: Abacavir Sulfate
DrugBank: Abacavir (DB01048)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT05432947
Drug: 68Ga-P16-093
RxNorm normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 68Ga-P16-093 with a dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg.
Trial: NCT05432947
Drug: 18F-FDG
RxNorm normalized name: 18F-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 18F-FDG with a dosage of 5.55 MBq (0.15 mCi)/kg.
Trial: NCT05170503
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab 200mg iv drip. Qd D1 + Oxaliplatin 130/m2 iv drip. Qd D1 + Tegafur (Gimeracil and Oteracil Potassium Capsules) \[40mg/m2 if BSA \<1.25m2, 50mg/m2 if BSA ≥1.25m2 \& \<1.5m2, 60mg/m2 if BSA ≥1.5m2\] po. Bid D1-14 for three cycles
Trial: NCT05716854
Drug: Pimozide
RxNorm normalized name: Pimozide
DrugBank: Pimozide (DB01100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects receive the Pimozide intervention orally according to the following schedule:~Days 1-3: Pimozide 6 mg immediate release (IR) once per day.
Trial: NCT04680988
Drug: SHR-1210
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1210 intravenously every 3 weeks
Trial: NCT04680988
Drug: SHR-1020
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1020 Orally once daily
Trial: NCT05716854
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects receive Moxifloxacin 800 mg orally once on day 1.
Trial: NCT05716854
Drug: Cobicistat
RxNorm normalized name: Cobicistat
DrugBank: Cobicistat (DB09065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects receive Cobicistat 450 mg orally once on day 1.
Trial: NCT05716854
Drug: Moxifloxacin and Cobicistat
RxNorm normalized name: darunavir and cobicistat
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects receive Moxifloxacin 800 mg and Cobicistat 450 mg orally once on day 1.
Trial: NCT05249127
Drug: 64Cu-SAR-bisPSMA
RxNorm normalized name: 64Cu-dotatate
DrugBank: Copper oxodotreotide Cu-64 (DB15873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 64Cu-SAR-bisPSMA
Trial: NCT05375955
Drug: PF-07038124 ointment 0.01%
DrugBank: PF-07038124 (DB19143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atopic Dermatitis and Plaque Psoriasis
Trial: NCT05375955
Drug: Vehicle ointment
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atopic Dermatitis and Plaque Psoriasis
Trial: NCT05375955
Drug: PF-07038124 ointment 0.03%
DrugBank: PF-07038124 (DB19143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atopic Dermatitis and Plaque Psoriasis
Trial: NCT05375955
Drug: PF-07038124 ointment 0.06%
DrugBank: PF-07038124 (DB19143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-07038124 ointment 0.06% (Plaque Psoriasis only)
Trial: NCT05640245
Drug: Sonelokimab
RxNorm normalized name: Sonelokimab
DrugBank: Sonelokimab (DB18843)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: randomized treatment; parallel group
Trial: NCT05640245
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: randomized treatment; parallel-group
Trial: NCT05179772
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine (2.5 mg to 20 mg)
Trial: NCT05400395
Drug: GNX80
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GNX80 oral intake(BID) for 24 weeks
Trial: NCT06055244
Drug: Amantadine
RxNorm normalized name: Amantadine
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be give amantadine 100 mg twice daily.
Trial: NCT05330273
Drug: Ganaplacide
RxNorm normalized name: Ganaplacide
DrugBank: Ganaplacide (DB16173)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period 1: 400 mg (4 x 100 mg tablets) for oral administration Period 2: 400 mg (4 x 100 mg tablets) for oral administration
Trial: NCT05330273
Drug: Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Period 2: 600 mg (1 x 600 mg tablet) for oral administration once daily (q.d.)
Trial: NCT00385554
Drug: UC-781 carbomer gel, 0.1% and 0.25%
DrugBank: UC-781 (DB05871)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06437158
Drug: Bleomycin
RxNorm normalized name: Bleomycin
DrugBank: Bleomycin (DB00290)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To validated the efficacy and safety of different concentrations of Bleomycin in the sclerotherapy of lymphatic malformations for pediatric patients
Trial: NCT04343274
Drug: Tozuleristide
RxNorm normalized name: Tozuleristide
DrugBank: Tozuleristide (DB15375)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05520021
Drug: Nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A total of 30 pregnancies with preterm labor threats will be treated with Nifedipine.
Trial: NCT05520021
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A total of 30 pregnancies with preterm labor threats will be treated with Magnesium sulfate.
Trial: NCT05278338
Drug: Denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations
Trial: NCT04605393
Drug: Cannabidiol
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CBD
Trial: NCT04605393
Drug: Delta-9-THC
RxNorm normalized name: delta-9-THC
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: THC
Trial: NCT06505551
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: for 3 consecutive days
Trial: NCT01196208
Drug: brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Every 21 days by intravenous infusion (1.8 mg/kg)
Trial: NCT04683939
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV
Trial: NCT04683939
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV
Trial: NCT05709444
Drug: Bremelanotide
RxNorm normalized name: Bremelanotide
DrugBank: Bremelanotide (DB11653)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bremelanotide is a cyclic, heptapeptide analog of the endogenous peptide alpha melanocortin stimulating hormone (αMSH).
Trial: NCT05705115
Drug: Ringer acetate
DrugBank: COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection (DB15845)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer acetate 5 ml/kg.
Trial: NCT06622525
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This group will receive 100 mEq of sodium bicarbonate diluted in one liter of saline solution, administered at a rate of 100 ml/h, with the goal of maintaining a urinary pH greater than 6.5.
Trial: NCT06730503
Drug: Immune checkpoint inhibitor
RxNorm normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observe a situation before and after immunotherapy
Trial: NCT04882774
Drug: Treprostinil Diolamine
RxNorm normalized name: treprostinil diolamine
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral treprostinil 0.125 mg TID titrated as clinically indicated and tolerated to a maximum of 6 mg TID
Trial: NCT04936698
Drug: Levothyroxin
RxNorm normalized name: Levothyroxin
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: to treat if the patient has hypothyroidism
Trial: NCT05057117
Drug: Botulinum toxin A
RxNorm normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Baseline treatment with microwave thermolysis in one axilla and botulinum toxin A in the contralateral axilla, as allocated by randomization
Trial: NCT04999644
Drug: Full Nicotine Cigarettes
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A full nicotine tobacco cigarette that will be smoked by participants
Trial: NCT04999644
Drug: Reduced Nicotine Cigarettes
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A reduced nicotine tobacco cigarette that will be smoked by participants
Trial: NCT06243185
Drug: Dalpiciclib plus letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dalpiciclib 150mg qd, d1-21, repeated once every 4 weeks. Letrozole 2.5mg qd, repeated once every 4 weeks.
Trial: NCT06598371
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by IV
Trial: NCT06598371
Drug: Interleukin-2
RxNorm normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by IV
Trial: NCT06665971
Drug: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dosage form: Subcutaneous injection Dosage: 300 mg/ 2ml Dosage frequency: Once a week Duration: 12 weeks
Trial: NCT06383780
Drug: GP combined with Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine combined with cisplatin regimen combined with Tislelizumab
Trial: NCT06383780
Drug: TPC combined with Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cisplatin, nab-paclitaxel and capecitabine regimen combined with Tislelizumab
Trial: NCT04327661
Drug: Tradipitant
RxNorm normalized name: Tradipitant
DrugBank: Tradipitant (DB12580)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Capsule
Trial: NCT06381154
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06381154
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06381154
Drug: Verteporfin
RxNorm normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT05024526
Drug: edaravone dexborneol or edaravone
DrugBank: Borneol (DB11288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edaravone dexborneol or edaravone is going to be used in two different groups to compare the efficacy.
Trial: NCT04756986
Drug: malic acid
RxNorm normalized name: Malic Acid
DrugBank: Malic acid (DB12751)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% malic acid spray
Trial: NCT01874314
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400mg of moxifloxacin (positive control) administered orally, once daily for 7 days.
Trial: NCT05995301
Drug: Ropivacaine in Transversus abdominis plane
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This group received 20ml of Ropivacaine 0.2% Injectable Solution in bilateral transversus abdominis plane at the end of surgery
Trial: NCT05995301
Drug: Ropivacaine in Local infiltration at port site
RxNorm normalized name: AT-7519
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This group received local infiltration of 20ml of Ropivacaine 0.2% Injectable Solutionat port sites at the end of surgery
Trial: NCT04466215
Drug: Miricorilant
RxNorm normalized name: Miricorilant
DrugBank: Miricorilant (DB16234)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg (6 x 150 mg) tablets taken orally once daily for two weeks
Trial: NCT06406634
Drug: Cadonilimab
RxNorm normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable solution
Trial: NCT06406634
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: capsule
Trial: NCT01425567
Drug: Intravenous Lipid Emulsion Comprised of Fish Oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV lipid provided for parenteral nutrition when enteral feeds are not tolerated due to intestinal disease
Trial: NCT05673876
Drug: GDC-8264
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GDC-8264 tablets will be administered as per the schedule specified in the respective arms.
Trial: NCT00414739
Drug: Benzalkonium chloride
RxNorm normalized name: Benzalkonium Chloride
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no